<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04966455</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT04966455</nct_id>
  </id_info>
  <brief_title>Effect of Raisins on Cognitive Function in Healthy Older Adults</brief_title>
  <official_title>Effect of Supplementing the Diet With Raisins, a Food Rich in Polyphenols, on Cognitive Function in Healthy Older Adults, a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Salamanca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Salamanca</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:To assess the effect of an intervention based on including 50 g of raisins&#xD;
      (sultanas) daily in the diet for 3 months on improving cognitive performance, cardiovascular&#xD;
      risk factors and inflammatory markers in a population of older adults without cognitive&#xD;
      impairment.&#xD;
&#xD;
      Methodology: Randomised two parallel-group clinical trial. Population: 80 patients between 70&#xD;
      and 80 years of age will be included, selected from primary care clinics in Salamanca and&#xD;
      Zamora.&#xD;
&#xD;
      Measurements and intervention: Participants included in the study will have a baseline visit&#xD;
      and two evaluations visits at 3 and 6 months where cognitive performance (attention,&#xD;
      executive functions, verbal memory, working memory and language) will be assessed using a&#xD;
      brief neuropsychological battery; quality of life, using the WHOQol- AGE and EUROQOL-5D&#xD;
      questionnaire; blood pressure; glycaemia; body composition, using an impedancemeter; and&#xD;
      different markers of inflammation, interleukin (IL) 6, IL-1 and tumour necrosis factor alpha&#xD;
      (TNF); and different markers of inflammation, interleukin (IL) 6, IL-1 and tumour necrosis&#xD;
      factor alpha (TNF-α).&#xD;
&#xD;
      Participants will be randomised using the Epidat 4.0 programme into 2 groups (control group&#xD;
      and intervention group) with a ratio of 1:1. Both groups will be instructed to continue with&#xD;
      their usual dietary pattern without changing their habits during the study period.&#xD;
&#xD;
      Those in the control group will not receive any amount of raisins to their usual diet. The&#xD;
      participants in the intervention group will receive 50 g of raisins and instructions on the&#xD;
      time of day to take it (at night). The duration of this intervention will be 3 months. The&#xD;
      daily nutritional intake of this amount of raisins is as follows: 146 kcal; 0.25 g of fat; 34&#xD;
      g carbohydrates of which 34 g sugars; 1.3 g protein; 1 g fibre. The total polyphenol content&#xD;
      of total polyphenols from 50 g of raisinas is approximately 532,5 mg (phenols explorer&#xD;
      database).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2021</start_date>
  <completion_date type="Anticipated">October 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive impairment</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluated by Montreal Cognitive Assessment (MoCA). Score (0-30). 30 (better score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluated by EuroQoL-5D-3L (EuroQol Visual Analogue Scale (EQ-VAS)) Range 0-100. 100 (best quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluated by EuroQoL-5D-3L (EQ-5D summary index ) Range 0-1. 1 (best quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluated by WHOQOL-AGE. Total score Range 0-65. 65 (best quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>3 months</time_frame>
    <description>Measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma cholesterol</measure>
    <time_frame>3 months</time_frame>
    <description>Measured in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker (IL-6</measure>
    <time_frame>3 months</time_frame>
    <description>Measured in pg/ml</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cognitive Dysfunction</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supplementation of 50 g daily of rainsins for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Raisins</intervention_name>
    <description>Daily supplementation of 50 g of rainsins for 3 months</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  People of both sexes aged between 70 and 80 years.&#xD;
&#xD;
          -  The score on the Mini Mental State Examination (MMSE) must be greater than or equal to&#xD;
             24 points.&#xD;
&#xD;
          -  Self-employed to attend the centre where the study is carried out.&#xD;
&#xD;
          -  Signature of the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coronary or cerebrovascular atherosclerotic pathology.&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Grade II or higher heart failure.&#xD;
&#xD;
          -  Moderate or severe chronic obstructive pulmonary disease.&#xD;
&#xD;
          -  Advanced renal or hepatic disease.&#xD;
&#xD;
          -  Severe mental illness.&#xD;
&#xD;
          -  Oncological disease under treatment diagnosed within the last 5 years or terminal&#xD;
             condition.&#xD;
&#xD;
          -  Morbid obesity (IMC ≥ 40 kg/m2).&#xD;
&#xD;
          -  Intolerance and/or allergy to any of the grape components.&#xD;
&#xD;
          -  Any other circumstance at the criterion of the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose I Recio-Rodriguez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Salamanca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose I Recio-Rodriguez, PhD</last_name>
    <phone>0034 663176041</phone>
    <email>donrecio@usal.es</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Salamanca</investigator_affiliation>
    <investigator_full_name>José Ignacio Recio Rodriguez</investigator_full_name>
    <investigator_title>PhD in Biosciences, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cognitive dysfunction</keyword>
  <keyword>Heart Disease Risk Factors</keyword>
  <keyword>Vitis</keyword>
  <keyword>Polyphenols</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

